Change in the total number of shares and votes in Recipharm AB (publ)

As of 29 June 2018, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 67,775,793 shares, divided into 15,222,858 shares of series A, 52,182,935 shares of series B and 370,000 shares of series D. The total number of votes in Recipharm as of 29 June 2018 amounts to 204,781,515.

As previously announced by Recipharm, the number of shares and votes in Recipharm has increased as a result of a cash issue of 4,000,000 shares of series B raising SEK 508 million to Recipharm before issue costs, and an issue in kind of 558,261 shares of series B in the amount of approximately SEK 71.6 million.

For more information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Karl Lindström, CFO, telephone: +46 8 602 53 11, ir@recipharm.com

This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980). This information was submitted for publication on 29 June 2018, at 08:00 am CET. 

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com